RPS2 Polypeptide Composition for Multi-Metric Metabolic Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes, particularly Type 2, often require combination therapies that increase the risk of side effects, and there is a need for a therapeutic composition that can effectively lower blood glucose, blood pressure, and cholesterol levels without these side effects.
Innovation Solution
A pharmaceutical composition comprising a polypeptide corresponding to an active region of the 40S ribosomal protein S2 (RPS2) or its analogues, which can be administered orally or intravenously to reduce blood glucose levels, insulin resistance, hepatic glucose production, glucagon levels, blood pressure, and cholesterol levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple pharmaceutical medications are used together as combination therapy to treat Type 2 diabetes, then treatment effectiveness is improved, but the likelihood of unwanted side effects increases
Solution Approach 1:
The patent applies universality by developing a single pharmaceutical composition that performs multiple therapeutic functions simultaneously. The composition reduces blood glucose levels, modulates blood pressure, and lowers cholesterol levels, thereby treating diabetes, hypertension, and hypercholesterolemia with one agent instead of multiple medications, reducing side effects while maintaining treatment effectiveness
Solution Approach 2:
The patent merges multiple therapeutic activities into one unified pharmaceutical composition. By combining glucose-lowering, blood pressure modulation, and cholesterol reduction effects in a single composition, the patent eliminates the need for combination therapy with multiple drugs, thereby reducing the cumulative side effects while achieving comprehensive metabolic control
2Reliability
If insulin administration is used to treat Type 1 diabetes, then blood glucose control is achieved, but long-term complications occur due to difficulty in determining exact insulin dosage
Solution Approach 1:
The patent applies parameter changes by modifying the therapeutic approach from insulin-based glucose control to a composition that simultaneously addresses glucose, blood pressure, and cholesterol parameters. This multi-parameter approach provides more comprehensive metabolic control with potentially easier dosage management, as the single composition addresses multiple physiological parameters rather than requiring precise insulin dosing calculations
3Reliability
If conventional drugs are used to treat hypertension, high cholesterol and diabetes, then these conditions are managed, but side effects occur to varying degrees
Solution Approach 1:
The patent applies universality by creating a single pharmaceutical composition that simultaneously manages diabetes, hypertension, and hypercholesterolemia. The composition reduces blood glucose levels, modulates blood pressure, and lowers cholesterol levels, providing comprehensive management of all three conditions with one agent, thereby eliminating the side effects associated with multiple conventional medications
Data Source
AI summary
The present invention provides a pharmaceutical formulation comprising a therapeutically effective amount of a polypeptide corresponding to one or more of SEQ ID No(s) 1, 2, 3 or 4. The therapeutically effective amount of polypeptide may be formulated for administration to a subject in need of treatment as an oral formulation, a parenteral formulation, a topical formulation, an aqueous formulation, a solid formulation, a lyophilized formulation, or a trans-dermal formulation. Also disclosed are methods for treating at least one of diabetes, hyperglycemia, hypercholesterolemia, and hypertension in a subject, comprising administering to the subject a therapeutically effective amount of a polypeptide according to SEQ ID Nos. 1-4.